Boundless Bio
BOLD
47 hedge funds and large institutions have $53.4M invested in Boundless Bio in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 17 closing their positions.
62.18% more ownership
Funds ownership: 0% → 62.18% (+62%)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
9% more funds holding
Funds holding: 43 → 47 (+4)
74% less capital invested
Capital invested by funds: $209M → $53.4M (-$155M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.51M |
| 2 |
Morgan Stanley
New York
|
+$1.79M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$1.1M |
| 4 |
Millennium Management
New York
|
+$1.06M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.34M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.45M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.14M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.3M |
BOLD Hedge Fund Activity: Q2 2024 in Review
47 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q2 2024, worth a combined $53.4M — down 74% from $209M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new BOLD positions and 17 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $3.51M. The largest seller was Federated Hermes, exiting entirely with an estimated $5.34M sold.
- 47 institutional investors held Boundless Bio (BOLD) as of Q2 2024, up from 43 in Q1 2024.
- Funds reported $53.4M of Boundless Bio stock for Q2 2024, down 74% quarter-over-quarter.
- 21 funds opened new Boundless Bio positions in Q2 2024 and 17 closed out, a net change of +4 holders.
- The largest Boundless Bio buyer in Q2 2024 was BlackRock, an estimated $3.51M added.
- The largest Boundless Bio seller in Q2 2024 was Federated Hermes, an estimated $5.34M sold.
Based on aggregated 13F filings for Q2 2024.